Bayer Discontinues Trasylol(R) Clinical Trial Program In Non-CABG Indications
Fri, 26 Jan 2007 08:00 AM EST
... Bayer HealthCare has decided to end three ongoing clinical studies investigating the safety and efficacy of Trasylol(R) (aprotinin injection) on transfusion requirements and blood loss in adults undergoing: elective spinal fusion surgery, pneumonectomy or esophagectomy for cancer, and radical or total cystectomy in bladder cancer. [click link for full article] ...
Related Topics
- Clinical Trials
- Coronary Artery Bypass Graft
- Aprotinin
- Aspirin
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Health psychology
- Patient Issues
- Tarceva
- Bevacizumab Injection
- Clinical Growth Charts
- Crohn's Disease
- Pancreatic Cancer
- Cardiovascular Health
- Hypnotherapy
- Epidemiology
- Clinical Laboratory Improvement Amendments
- Depression
- Infectious Diseases

Not Signed In -


